bioSyntagma is motivated to make a difference in the lives of patients because we believe that treatment success should not be measured in months of survival but in cases cured.
Who We Are
Our mission is to give cancer patients more time with their families by eliminating trial-and-error cancer treatments.
Our vision is to move the healthcare system towards a sustainable future by enabling personalized medicine.
Our team is built on the following values:
• People first
• Fight for the mission
• Pursue excellence
• Unified in diversity
Are you looking for meaningful work in the biomedical industry? Email us at email@example.com
David Richardson, BSE, PSM
Chief Executive Officer
David Richardson is a founding member of bioSyntagma with 9 years’ experience in research & development. He has worked previously with other startup companies, successfully aiding the development and launch of multiple software packages used by government agencies to secure and control their facilities. He then transitioned into healthcare, engineering orthopedic solutions including surgical instruments, knee implant hardware, and a complete hip replacement system under FDA and ISO certified design systems. This included market research, design validation and verification, and documentation for 510(k) FDA approval. Mr. Richardson then moved into cancer research as an engineer where he fabricated a microfluidic system capable of investigating living micro tumor spheroids at the single-cell level.
Dmitry Derkach, MD, PhD
Chief Scientific Officer
Dmitry Derkach is a founding member of bioSyntagma with a background in Molecular and Cellular Biology as well as clinical practice as an MD. Dr. Derkach has almost 20-years lab and industrial experience in drug/bioassay development, validation and implementation. Dr. Derkach practiced medicine for 4 years in the ICU before advancing to achieve his PhD in Molecular Biology at Kyushu University (Japan) and postdoctoral work at University of Arizona. He moved to a pharmaceutical company in Phoenix, AZ where he developed two cell based potency assays and elucidated mechanisms of action for two peptide based drugs. His 5-years in FDA regulated lab work was focused on developing peptide-based drugs for use in the US market. In 2013 Dr. Derkach joined the Biodesign Institute developing novel, high-throughput genomic screening tools.